|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024204,
umls-concept:C0026777,
umls-concept:C0030705,
umls-concept:C0079419,
umls-concept:C0205160,
umls-concept:C0220901,
umls-concept:C0439234,
umls-concept:C0678222,
umls-concept:C1514474,
umls-concept:C1522577,
umls-concept:C1522609,
umls-concept:C1554112
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-3-8
|
|
pubmed:abstractText |
Approximately 30% of breast carcinoma patients with negative lymph nodes die of their disease. Biologic markers such p53 protein and c-erb B-2 have been related to tumor progression, but their prognostic value remains controversial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
804-13
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:10679650-Adult,
pubmed-meshheading:10679650-Aged,
pubmed-meshheading:10679650-Breast Neoplasms,
pubmed-meshheading:10679650-Carcinoma,
pubmed-meshheading:10679650-Disease-Free Survival,
pubmed-meshheading:10679650-Female,
pubmed-meshheading:10679650-Follow-Up Studies,
pubmed-meshheading:10679650-Humans,
pubmed-meshheading:10679650-Immunohistochemistry,
pubmed-meshheading:10679650-Lymphatic Metastasis,
pubmed-meshheading:10679650-Middle Aged,
pubmed-meshheading:10679650-Multivariate Analysis,
pubmed-meshheading:10679650-Prognosis,
pubmed-meshheading:10679650-Receptor, erbB-2,
pubmed-meshheading:10679650-Receptors, Estrogen,
pubmed-meshheading:10679650-Receptors, Progesterone,
pubmed-meshheading:10679650-Survival Rate,
pubmed-meshheading:10679650-Tumor Markers, Biological,
pubmed-meshheading:10679650-Tumor Suppressor Protein p53
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
|
|
pubmed:affiliation |
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
|
|
pubmed:publicationType |
Journal Article
|
